晚期卵巢癌新辅助化疗的真实世界结局:从未接受手术的患者会怎样
这项回顾性队列研究纳入2017至2022年开始至少三周期化疗的III/IV期上皮性卵巢癌患者176例,138例(78.4%)接受间歇性肿瘤细胞减灭术(ICS),38例(21.6%)仅接受化疗。仅化疗组3年无进展生存率和总生存率均低于ICS组,多因素分析中仅化疗与复发和死亡独立相关。作者认为对化疗有反应、适合手术且手术成功可能性合理的患者应继续推荐间歇手术。
要点
- 176例中38例(21.6%)开始化疗后从未接受肿瘤细胞减灭术
- 仅化疗组3年无进展生存率7.2%对ICS组22.0%,总生存率14.0%对61.1%
- 多因素分析中仅化疗与复发(aHR 2.58)和死亡(aHR 4.60)独立相关
核心结论
- 相当比例的晚期卵巢癌患者开始化疗后从未接受肿瘤细胞减灭术。
- 间歇手术在多数情况下似乎有益,因此对化疗有反应、适合手术且手术成功可能性合理的患者应继续推荐间歇手术。
研究设计与样本
- 回顾性队列研究,纳入2017至2022年开始至少三周期化疗的III/IV期上皮性卵巢癌患者176例。
- 主要分析比较接受间歇性肿瘤细胞减灭术(ICS)者与仅接受化疗者(计划ICS未实施)的3年无进展生存率和总生存率。
- 次要分析按ICS时机和最佳手术候选资格分层。
- 总生存率采用Kaplan-Meier曲线和Cox比例风险模型报告,包括单变量和多变量分析,并控制临床和统计学显著的协变量。
主要发现
- 176例患者中138例(78.4%)接受ICS,38例(21.6%)仅接受化疗。
- 仅化疗组患者年龄更大、合并症更多、体能状态更差且白蛋白更低。
- 两组在治疗前分期、组织学类型和CA-125正常化方面相似。
- 仅化疗组3年无进展生存率7.2%对ICS组22.0%,3年总生存率14.0%对61.1%。
- 多因素分析中,仅接受化疗与复发独立相关(校正风险比2.58;95%置信区间1.63-4.10),与死亡独立相关(校正风险比4.60;95%置信区间2.43-8.71)。
临床怎么用
- 作者认为间歇手术在多数情况下似乎有益,应继续推荐用于对化疗有反应、适合手术且手术成功可能性合理的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the outcomes of patients with advanced ovarian cancer (OC) treated with neoadjuvant chemotherapy who do and do not undergo interval cytoreductive surgery (ICS). METHODS: This was a retrospective cohort study of patients with stage III/IV epithelial OC who began treatment with at least three cycles of chemotherapy from 2017 to 2022. Primary analysis compared 3-year progression-free (PFS) and overall (OS) survival for patients who underwent ICS to those who received chemotherapy only (planned ICS not performed). Secondary analyses stratified by timing of ICS and optimal surgical candidacy. We report OS based on Kaplan-Meier curves and Cox proportional hazards models, univariate and multivariate (MVA), controlling for clinically and statistically significant covariates. RESULTS: Of 176 patients, 138 (78.4 %) underwent ICS and 38 (21.6 %) underwent chemotherapy only. Chemotherapy-only patients were older and more comorbid with worse performance status and lower albumin. Groups were similar in pre-treatment stage, histology, and CA-125 normalization. Chemotherapy-only patients had shorter 3-year PFS and OS compared to ICS (3-year PFS 7.2 % vs 22.0 %; OS 14.0 % vs 61.1 %). In MVA, receiving chemotherapy only was independently associated with recurrence (adjusted hazard ratio (aHR) 2.58; 95 % confidence interval (CI) 1.63-4.10) and death (aHR 4.60; 95 % CI 2.43-8.71). CONCLUSIONS: A notable proportion of patients with advanced OC who begin treatment with chemotherapy will never undergo cytoreductive surgery. Interval surgery appears beneficial in most instances, and thus, should continue to be recommended for patients who demonstrate response to chemotherapy, are fit surgical candidates, and have a reasonable likelihood of a successful operation.
引用
- Bruce KH, Xu C, Shah RP, et al. Real-world outcomes of neoadjuvant chemotherapy for advanced ovarian cancer: What happens to patients who never undergo surgery? Gynecol Oncol. 2025. PMID: 40865188. doi:10.1016/j.ygyno.2025.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。